RioDerm-003 by Rion for Radiodermatitis: Likelihood of Approval

RioDerm-003 is under clinical development by Rion and currently in Phase I for Radiodermatitis.

BMS, VantAI team up; CRISPR Therapeutics to raise $280M; Ono Pharma’s deal with Shattuck Labs

Plus, news about Areteia Therapeutics, Sudo Biosciences, Cidara Therapeutics, Xspray Pharma and Sana Biotechnology: Bristol Myers Squibb inks deal with VantAI: The pair plan to

February 14, 2024

DOUGLAS continues sales and profit growth in third quarter – Biotech Investments

EQS-News: Douglas GmbH / Key word(s): 9 Month figures Douglas GmbH: DOUGLAS continues sales and profit growth in third quarter 24.08.2023 / 07:30 CET/CEST The

August 25, 2023

Will it soon be possible for doctors to use AI to detect and diagnose cancer?

Researchers developed binary and multiclass machine learning models to distinguish cancer from non-cancerous tissue samples.

June 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.